US Oncology Reports 2009 Fourth Quarter and Year End Operating Results
10 PERCENT INCREASE IN ADJUSTED EBITDA TO $241 MILLION FOR FISCAL 2009
THE WOODLANDS, TX, February 25, 2010 – US Oncology, Inc. (“US Oncology” or “the Company”), reported revenue growth in the fourth quarter of 2009 of 5.1 percent to $886.0 million from $842.7 million in the same period in 2008. Adjusted EBITDA increased by 10.7 percent in the fourth quarter of 2009 to $61.1 million from $55.2 million in the same period in 2008 (see definition of Adjusted EBITDA in “Discussion of Non-GAAP Information” in this release). Read release.
US Oncology announces expanded educational resources to cancer patients through new affiliations with CURE & NexCura